[Comment] Type 2 diabetes subtypes classification: a global reckoning with heterogeneity

For decades, type 2 diabetes has been managed as a monolithic condition, defined by hyperglycaemia and treated via uniform, stepwise algorithms. Although operationally convenient, this practice increasingly fails to account for the biological heterogeneity of type 2 diabetes. Just as oncology evolved from treating cancer as a single disease to recognising distinct malignancies with targeted therapies, a similar transformation is now underway in the field of type 2 diabetes.1 A syndromic framework grounded in molecular pathophysiology could ultimately reorient diabetes care towards precise, stratified risk prediction, personalised prevention, and targeted therapy.